Moichor

Moichor's AI-powered point-of-care device, Pathview, gains significant market traction, especially through the Zomedica partnership, capturing substantial share from legacy incumbents like IDEXX and Antech by offering superior accuracy and speed. This drives revenue to $50M+ by 2028, justifying a $330M+ valuation (2.75x current) at a premium multiple due to its technological edge and expanding species-specific reference interval library.

Moichor continues its strong growth, expanding its reference lab services and achieving moderate adoption of its Pathview device, competing effectively in niche segments (e.g., exotic animals) and with smaller clinics. Revenue reaches ~$25M by 2028, leading to an acquisition or IPO at a $210M valuation (1.75x current), reflecting solid execution but continued competition from larger players.

Incumbents like IDEXX and Antech accelerate their own AI diagnostic offerings or leverage their vast distribution networks to stifle Moichor's growth, particularly for the point-of-care device. Regulatory hurdles or slower-than-expected adoption of new technology by veterinarians also impact sales. Growth slows, and the company struggles to raise its next round at a higher valuation, leading to a down round or acquisition at a reduced valuation of $60M (-50% from current), significantly impacting common stock value.